← Back

Pharma & biotech

15 names · 8 named directly by the news · 11 affected

AMGNAmgen391.63 -10.43%
2 direct2 2nd-order
▲AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
MRNAModerna140.23 -3.66%
2 direct
▲The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
AZNAstraZeneca159.83 -1.76%
1 direct1 2nd-order
▲HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
PFEPfizer27.82 -2.22%
1 direct1 2nd-order
▲FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
BMYBristol Myers Squibb64.56 -3.39%
2 direct1 2nd-order
▲Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
MRKMerck148.71 -1.08%
3 direct1 2nd-order
▲MRK 8-K — Results of Operations and Financial Condition
GILDGilead145.89 -3.38%
1 direct
▼FDA Grants Accelerated Approval to a New Breast Cancer Treatment
LLYEli Lilly1120.79 -2.49%
1 direct1 2nd-order
▼FDA Grants Accelerated Approval to a New Breast Cancer Treatment
BIIBBiogen212.31 -3.86%
1 2nd-order
▲FDA Approves First Drug to Treat Alexander Disease
REGNRegeneron810.25 -2.11%
1 2nd-order
▼AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
NVONovo Nordisk45.25 -2.91%
1 2nd-order
▼3 Things That Matter Most for Eli Lilly Now
ABBVAbbVie248.69 -3.03%
—
—
JNJJohnson & Johnson269.29 -2.16%
—
—
VRTXVertex Pharmaceuticals528.18 -3.28%
—
—
ZTSZoetis73.94 -2.46%
—
—

Stock	Price	News impact	Strongest story
AMGN Amgen	391.63 -10.43%	2 direct2 2nd-order	▲AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
MRNA Moderna	140.23 -3.66%	2 direct	▲The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
AZN AstraZeneca	159.83 -1.76%	1 direct1 2nd-order	▲HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
PFE Pfizer	27.82 -2.22%	1 direct1 2nd-order	▲FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
BMY Bristol Myers Squibb	64.56 -3.39%	2 direct1 2nd-order	▲Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
MRK Merck	148.71 -1.08%	3 direct1 2nd-order	▲MRK 8-K — Results of Operations and Financial Condition
GILD Gilead	145.89 -3.38%	1 direct	▼FDA Grants Accelerated Approval to a New Breast Cancer Treatment
LLY Eli Lilly	1120.79 -2.49%	1 direct1 2nd-order	▼FDA Grants Accelerated Approval to a New Breast Cancer Treatment
BIIB Biogen	212.31 -3.86%	1 2nd-order	▲FDA Approves First Drug to Treat Alexander Disease
REGN Regeneron	810.25 -2.11%	1 2nd-order	▼AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
NVO Novo Nordisk	45.25 -2.91%	1 2nd-order	▼3 Things That Matter Most for Eli Lilly Now
ABBV AbbVie	248.69 -3.03%	—	—
JNJ Johnson & Johnson	269.29 -2.16%	—	—
VRTX Vertex Pharmaceuticals	528.18 -3.28%	—	—
ZTS Zoetis	73.94 -2.46%	—	—

Quotes are delayed. News impact decays over each event's persistence window and drops out when it expires; this page is for ranking at a glance — exact counts live on the stock page.

← All industries